Oct 2026
A biomimetic nanoplatform for targeted co-delivery of ABT-199 and ATRA potentiates acute myeloid leukemia therapy via DNA damage response suppression.
HPAA is established as a promising biomimetic nanoplatform for AML therapy by integrating active targeting with the novel drug repurposing of ATRA as a Chk1 suppressor to potentiate ABT-199 efficacy.
Zhi-Di He, Yu-Lin Xu, Zhi-Peng Tian et al.
· International journal of pha... · 0 citations